NDL neurodiscovery limited

beijing tide pharmaceuticals

  1. 2,306 Posts.
    lightbulb Created with Sketch. 19
    NDL is a shell with a great potential .


    Beijing Tide intends to conduct a proof of principle Phase II clinical trial at its sole discretion with respect to financing and clinical design. Importantly, Beijing Tide will maintain the current patent portfolio world-wide while it continues development in China. This would mean that upon clinical success or commercialisation in China, Sosei may choose to have certain territories outside China re- assigned to Sosei.
    The Sosei and Beijing Tide Assignment Agreement ensures the NSL-043 program can now potentially move forward into Phase II trial/s.
    NeuroDiscovery is pleased it continues to have a potentially significant commercial interest in the NSL-043 program.

    https://trading.nab.com.au/ComNews/20120813/01322546.pdf

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.